The Impact of Vaccination on COVID-19 Burden of Disease in the Adult and Elderly Population: A Systematic Review of Italian Evidence

Overview

Journal Vaccines (Basel)

Date 2023 May 27

PMID 37243115

Authors

Giovanna Elisa Calabro

Ciro Pappalardo

Floriana DAmbrosio

Michele Vece

Chiara Lupi

Alberto Lontano

Mattia Di Russo

Roberto Ricciardi

Chiara de Waure

Affiliations

Soon will be listed here.

Abstract

COVID-19 is a major global health threat, with millions of confirmed cases and deaths worldwide. Containment and mitigation strategies, including vaccination, have been implemented to reduce transmission and protect the population. We conducted two systematic reviews to collect nonrandomized studies investigating the effects of vaccination on COVID-19-related complications and deaths in the Italian population. We considered studies conducted in Italian settings and written in English that contained data on the effects of vaccination on COVID-19-related mortality and complications. We excluded studies that pertained to the pediatric population. In total, we included 10 unique studies in our two systematic reviews. The results showed that fully vaccinated individuals had a lower risk of death, severe symptoms, and hospitalization compared to unvaccinated individuals. The review also looked at the impact of vaccination on post-COVID-19 syndrome, the effectiveness of booster doses in older individuals, and nationwide adverse events. Our work highlights the crucial role that vaccination campaigns have played in reducing the burden of COVID-19 disease in the Italian adult population, positively impacting the pandemic trajectory in Italy.

Citing Articles

Association between excess mortality due to COVID-19, full vaccination coverage, smoking, hypertension, and gross domestic product per capita/purchasing power parity across 10 Southeast Asian Countries.

Midon M, Ngatu N, Kanda K, Hirao T, Miyatake N, Wada K IJID Reg. 2025; 14:100570.

PMID: 39967743 PMC: 11833341. DOI: 10.1016/j.ijregi.2025.100570.

Emerging SARS-CoV-2 Variants in Uganda in the Era of COVID-19 Vaccination.

Bbosa N, Kiiza R, Ssekagiri A, Namagembe H, Nabirye S, Kabuuka D Viruses. 2025; 16(12).

PMID: 39772170 PMC: 11680199. DOI: 10.3390/v16121860.

Impact of Vaccination Status on COVID-19 Severity and Pulmonary Involvement.

Laitin S, Baditoiu L, Laza R, Besliu R, Stoicescu E, Gug M Medicina (Kaunas). 2025; 60(12.

PMID: 39768801 PMC: 11678390. DOI: 10.3390/medicina60121919.

Scrutinizing the COVID-19 vaccine safety debate.

Bin Abdulrahman K, Bin Abdulrahman A Hum Vaccin Immunother. 2024; 20(1):2401646.

PMID: 39693192 PMC: 11540079. DOI: 10.1080/21645515.2024.2401646.

SARS-CoV-2 Infection Risk by Vaccine Doses and Prior Infections Over 24 Months: ProHEpiC-19 Longitudinal Study.

Toran-Monserrat P, Lamonja-Vicente N, Costa-Garrido A, Carrasco-Ribelles L, Quirant B, Boigues M JMIR Public Health Surveill. 2024; 10:e56926.

PMID: 39648969 PMC: 11606241. DOI: 10.2196/56926.

References

Bollyky T, Gostin L, Hamburg M . The Equitable Distribution of COVID-19 Therapeutics and Vaccines. JAMA. 2020; 323(24):2462-2463. DOI: 10.1001/jama.2020.6641. View

Ng O, Marimuthu K, Lim N, Lim Z, Thevasagayam N, Koh V . Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore. JAMA Netw Open. 2022; 5(8):e2228900. PMC: 9419014. DOI: 10.1001/jamanetworkopen.2022.28900. View

Liang L, Kuo H, Ho H, Wu C . COVID-19 vaccinations are associated with reduced fatality rates: Evidence from cross-country quasi-experiments. J Glob Health. 2021; 11:05019. PMC: 8285768. DOI: 10.7189/jogh.11.05019. View

Wang Z, Schmidt F, Weisblum Y, Muecksch F, Barnes C, Finkin S . mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature. 2021; 592(7855):616-622. PMC: 8503938. DOI: 10.1038/s41586-021-03324-6. View

Haas E, McLaughlin J, Khan F, Angulo F, Anis E, Lipsitch M . Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study. Lancet Infect Dis. 2021; 22(3):357-366. PMC: 8457761. DOI: 10.1016/S1473-3099(21)00566-1. View

Mattiuzzi C, Lippi G . Efficacy of the Second COVID-19 Vaccine Booster Dose in the Elderly. Vaccines (Basel). 2023; 11(2). PMC: 9959889. DOI: 10.3390/vaccines11020213. View

Mattiuzzi C, Lippi G . Efficacy of COVID-19 vaccine booster doses in older people. Eur Geriatr Med. 2022; 13(1):275-278. PMC: 8784276. DOI: 10.1007/s41999-022-00615-7. View

Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A . Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016; 5(1):210. PMC: 5139140. DOI: 10.1186/s13643-016-0384-4. View

Notarte K, Catahay J, Velasco J, Pastrana A, Ver A, Pangilinan F . Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: A systematic review. EClinicalMedicine. 2022; 53:101624. PMC: 9417563. DOI: 10.1016/j.eclinm.2022.101624. View

10.

Rivasi G, Bulgaresi M, Mossello E, Buscemi P, Lorini C, Balzi D . Course and Lethality of SARS-CoV-2 Epidemic in Nursing Homes after Vaccination in Florence, Italy. Vaccines (Basel). 2021; 9(10). PMC: 8537408. DOI: 10.3390/vaccines9101174. View

11.

Nunes B, Rodrigues A, Kislaya I, Cruz C, Peralta-Santos A, Lima J . mRNA vaccine effectiveness against COVID-19-related hospitalisations and deaths in older adults: a cohort study based on data linkage of national health registries in Portugal, February to August 2021. Euro Surveill. 2021; 26(38). PMC: 8462036. DOI: 10.2807/1560-7917.ES.2021.26.38.2100833. View

12.

Widge A, Rouphael N, Jackson L, Anderson E, Roberts P, Makhene M . Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination. N Engl J Med. 2020; 384(1):80-82. PMC: 7727324. DOI: 10.1056/NEJMc2032195. View

13.

Chavda V, Vuppu S, Mishra T, Kamaraj S, Patel A, Sharma N . Recent review of COVID-19 management: diagnosis, treatment and vaccination. Pharmacol Rep. 2022; 74(6):1120-1148. PMC: 9549062. DOI: 10.1007/s43440-022-00425-5. View

14.

Ssentongo P, Ssentongo A, Voleti N, Groff D, Sun A, Ba D . SARS-CoV-2 vaccine effectiveness against infection, symptomatic and severe COVID-19: a systematic review and meta-analysis. BMC Infect Dis. 2022; 22(1):439. PMC: 9077344. DOI: 10.1186/s12879-022-07418-y. View

15.

Goel R, Painter M, Apostolidis S, Mathew D, Meng W, Rosenfeld A . mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. Science. 2021; 374(6572):abm0829. PMC: 9284784. DOI: 10.1126/science.abm0829. View

16.

Goldberg Y, Mandel M, Bar-On Y, Bodenheimer O, Freedman L, Haas E . Waning Immunity after the BNT162b2 Vaccine in Israel. N Engl J Med. 2021; 385(24):e85. PMC: 8609604. DOI: 10.1056/NEJMoa2114228. View

17.

Lauring A, Tenforde M, Chappell J, Gaglani M, Ginde A, McNeal T . Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study. BMJ. 2022; 376:e069761. PMC: 8905308. DOI: 10.1136/bmj-2021-069761. View

18.

Thompson M, Natarajan K, Irving S, Rowley E, Griggs E, Gaglani M . Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August.... MMWR Morb Mortal Wkly Rep. 2022; 71(4):139-145. PMC: 9351525. DOI: 10.15585/mmwr.mm7104e3. View

19.

Goldstein J, Cassidy T, Wachter K . Vaccinating the oldest against COVID-19 saves both the most lives and most years of life. Proc Natl Acad Sci U S A. 2021; 118(11). PMC: 7980436. DOI: 10.1073/pnas.2026322118. View

20.

Tartof S, Slezak J, Fischer H, Hong V, Ackerson B, Ranasinghe O . Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet. 2021; 398(10309):1407-1416. PMC: 8489881. DOI: 10.1016/S0140-6736(21)02183-8. View